Table 4.
Proportions of subjects in the UK Biobank participants estimated to have a hazard ratio of no less than 2.00, 2.50, or 3.00 of site-specific cancer*
| Cancers† | HR ≥ 2.00 |
HR ≥ 2.50 |
HR ≥ 3.00 |
|---|---|---|---|
| No. of subjects (%) | No. of subjects ( %) | No. of subjects ( %) | |
| Prostate | 52 185 (28.0) | 26 091 (14.0) | 13 045 (7.0) |
| Breast | 42 887(20.0) | 15 010 (7.0) | 4288 (2.0) |
| Colorectal | 40 072 (10.0) | 12 024 (3.0) | 3206 (0.8) |
| Lung | 400 (0.1) | 200 (0.05) | 0 (0) |
| Kidney | 2404 (0.6) | 1603 (0.4) | 1202 (0.3) |
| Bladder | 0 (0) | 0 (0) | 0 (0) |
| Ovary | 17 152 (8.0) | 8575 (4.0) | 0 (0) |
| Pancreas | 36 070 (9.0) | 16 031 (4.0) | 1202 (0.3) |
| Total ‡ | 161 723 (40.4) | 74 261 (18.5) | 22 638 (5.7) |
*
Hazard ratios (HRs) were estimated using Cox regression and adjusted for age, birth cohort, genotyping array, top 10 principal components for ancestry, and sex (for nonsex-specific cancer only), with middle quintile (40%-60%) as reference group.
†
Percentage of cancer of the prostate, breast, or ovary was calculated among men and women separately.
‡
Number of subjects who had an elevated risk of at least one site-specific cancer. Individuals who were at high risk of multiple cancers were only counted once.